» Articles » PMID: 23040116

Increased Exhaled Nitric Oxide Levels After Exercise in Patients with Chronic Systolic Heart Failure with Pulmonary Venous Hypertension

Overview
Journal J Card Fail
Date 2012 Oct 9
PMID 23040116
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fractional exhaled nitric oxide (eNO) is recognized as a marker of pulmonary endothelial function. Oxidative stress is associated with systemic endothelial nitric oxide production, but its correlation with eNO in heart failure (HF) patients has not been described. Previous studies have reported increased eNO levels after exercise in symptomatic HF patients but decreased levels with pulmonary arterial hypertension. Our objective was to prospectively examine the potential myocardial and functional determinants of exercise-induced rise of eNO in HF.

Methods And Results: Thirty-four consecutive ambulatory patients with chronic systolic HF (left ventricular ejection fraction [LVEF] ≤45%) underwent symptom-limited cardiopulmonary stress testing and echocardiography. eNO was determined immediately after exercise. Systemic endothelial dysfunction was assessed by asymmetric dimethylarginine (ADMA) and the L-arginine/ADMA ratio. In our study cohort (mean age 53 ± 13 years, 76% male, median LVEF 31%, interquartile range [IQR] 25%-40%), the mean eNO was 23 ± 9 ppb. eNO levels were higher in patients with diastolic dysfunction stages 2 or 3 than stage 1 or normal diastology (26.1 ± 9 vs 19.5 ± 7 ppb; P = .013). eNO had a positive correlation with estimated systolic pulmonary artery pressure (r = 0.57; P = .0009) and indexed left atrium volume (r = 0.43; P = .014), but it did not correlate with cardiopulmonary exercise test parameters, ADMA, or symptom score.

Conclusions: In contrast to earlier reports, the increase in postexercise eNO observed in stable chronic systolic HF patients may be attributed to the presence of underlying pulmonary venous hypertension probably secondary to advanced diastolic dysfunction.

Citing Articles

Breathomics Detect the Cardiovascular Disease: Delusion or Dilution of the Metabolomic Signature.

Marzoog B Curr Cardiol Rev. 2024; 20(4):e020224226647.

PMID: 38318837 PMC: 11327829. DOI: 10.2174/011573403X283768240124065853.


Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases.

Ragnoli B, Radaeli A, Pochetti P, Kette S, Morjaria J, Malerba M Ther Adv Chronic Dis. 2023; 14:20406223231190480.

PMID: 37538344 PMC: 10395178. DOI: 10.1177/20406223231190480.


Exhaled Biomarkers for Point-of-Care Diagnosis: Recent Advances and New Challenges in Breathomics.

Kiss H, Orlos Z, Gellert A, Megyesfalvi Z, Mikaczo A, Sarkozi A Micromachines (Basel). 2023; 14(2).

PMID: 36838091 PMC: 9964519. DOI: 10.3390/mi14020391.


Effectiveness of exhaled nitric oxide for the prediction of non-invasive left atrial pressure in older people: a cross-sectional cohort study.

Jones S, Londahl M, Prothero A, Hobbs F, Pavord I, Myerson S BJGP Open. 2022; 7(1).

PMID: 36332908 PMC: 10354326. DOI: 10.3399/BJGPO.2022.0105.


Clinical Value of FeNO for Pulmonary Hypertension Diagnosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Guo W, Wang N, Cui Z, Liu W, Guo S, Yang X Emerg Med Int. 2022; 2022:9924047.

PMID: 35127179 PMC: 8816608. DOI: 10.1155/2022/9924047.


References
1.
Rodway G, Choi J, Hoffman L, Sethi J . Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications. Chron Respir Dis. 2009; 6(1):19-29. PMC: 2724767. DOI: 10.1177/1479972308095936. View

2.
Takalo R, Piirila P, Sovijarvi A . Repeatability of successive measurements with a portable nitric oxide analyser in patients with suggested or diagnosed asthma. Scand J Clin Lab Invest. 2008; 68(8):830-2. DOI: 10.1080/00365510802621158. View

3.
Green C, Porter C, Bresnahan D, Spertus J . Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000; 35(5):1245-55. DOI: 10.1016/s0735-1097(00)00531-3. View

4.
Mullens W, Abrahams Z, Francis G, Sokos G, Starling R, Young J . Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009; 103(8):1113-9. PMC: 2856942. DOI: 10.1016/j.amjcard.2008.12.028. View

5.
Tang W, Wang Z, Cho L, Brennan D, Hazen S . Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol. 2009; 53(22):2061-7. PMC: 2755213. DOI: 10.1016/j.jacc.2009.02.036. View